Congenital Hematological Disorder Completed Phase 2 Trials for Concizumab (DB12820)

Back to Congenital Hematological Disorder

Also known as: Congenital bleeding disorders / Congenital Bleeding Disorder / Congenital haematological disorder

IndicationStatusPhase
DBCOND0081791 (Congenital Hematological Disorder)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03196284A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With InhibitorsTreatment